
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova has demonstrated a positive financial trajectory, evident in a mid-single-digit revenue growth of 6.7% for 2024, with expectations of organic growth in the cardiopulmonary segment of 7.0-8.0% for 2025. The company's gross margin improved by 160 basis points year-over-year, alongside an operating margin increase of 180 basis points, driven by gross margin expansion and effective management of selling, general, and administrative expenses. Furthermore, LivaNova anticipates a strengthening in revenue as elective procedures rebound post-COVID-19, combined with ongoing improvements in production capacity for oxygenators projected at an additional 10-15% increase in 2025.
Bears say
LivaNova's recent performance indicates a concerning trend, with neuromodulation sales experiencing a significant slowdown, growing only 1.0% to $137.6 million, which fell short of expectations and represents a decline from previous quarters' growth rates. Additionally, despite an 11.2% increase in cardiopulmonary sales to $181.7 million, this growth rate has also diminished from earlier periods, suggesting potential challenges in sustaining momentum in both core business segments. The company's guidance for revenue growth trending towards low-single digits, combined with operating margin contraction and underperformance in earnings relative to consensus expectations, reinforces a negative outlook on its future financial prospects.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares